Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis

Company Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $30.93 to $31.39
• 50-Day Range: $30.29 to $33.43
• 52-Week Range: $25.55 to $40.28
• Volume: 1.10 million shs
• Average Volume: 482,463 shs
• Market Capitalization: $1.74 billion
• P/E Ratio: 28.07
• Dividend Yield: N/A
• Price Target: $36.00
• Consensus Rating: Hold

Supernus Pharmaceuticals Stock Analysis - MarketRank™

Supernus Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 658th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Supernus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Supernus Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -39.50%

Earnings Growth

Earnings for Supernus Pharmaceuticals are expected to decrease by -39.50% in the coming year, from $2.38 to $1.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Supernus Pharmaceuticals is 28.07, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.96.

Price to Earnings Ratio vs. Sector

The P/E ratio of Supernus Pharmaceuticals is 28.07, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.95.

Price to Book Value per Share Ratio

Supernus Pharmaceuticals has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.61% of the float of Supernus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Supernus Pharmaceuticals has recently decreased by 4.73%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Supernus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Supernus Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.35

Percentage of Shares Shorted

7.61% of the float of Supernus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Supernus Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Supernus Pharmaceuticals has recently decreased by 4.73%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.38

News Sentiment

Supernus Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Supernus Pharmaceuticals this week, compared to 6 articles on an average week.

MarketBeat Follows

Only 1 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Supernus Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.80% of the stock of Supernus Pharmaceuticals is held by insiders.

SUPN Stock Analysis - Frequently Asked Questions

How have SUPN shares performed this year?

Supernus Pharmaceuticals' stock was trading at $36.16 on January 1st, 2025. Since then, SUPN stock has decreased by 13.8% and is now trading at $31.16.
View the best growth stocks for 2025 here.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings data on Monday, November, 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. The firm's revenue was up 14.2% compared to the same quarter last year.
Read the conference call transcript.

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' top institutional shareholders include Vanguard Group Inc. (11.01%), Armistice Capital LLC (9.28%), Stephens Investment Management Group LLC (3.11%) and GW&K Investment Management LLC (2.48%). Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Georges Gemayel, Padmanabh P Bhatt, Frank Mottola and Jonathan Rubin.
View institutional ownership trends.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 11/04/2024
• Today: 6/28/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SUPN
• CIK: 1356576
• Web: www.supernus.com
• Phone: (301) 838-2500
• Fax: 301-838-2501
• Employees: 580
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $36.00
• High Stock Price Target: $36.00
• Low Stock Price Target: $36.00
• Potential Upside/Downside: +15.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.11
• Trailing P/E Ratio: 28.07
• Forward P/E Ratio: 13.09
• P/E Growth: N/A
• Net Income: $73.86 million
• Net Margins: 9.27%
• Pretax Margin: 13.74%
• Return on Equity: 12.23%
• Return on Assets: 9.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.44
• Quick Ratio: 2.26

Sales & Book Value

• Annual Sales: $661.82 million
• Price / Sales: 2.64
• Cash Flow: $4.17 per share
• Price / Cash Flow: 7.48
• Book Value: $18.76 per share
• Price / Book: 1.66

Miscellaneous

• Outstanding Shares: 55,990,000
• Free Float: 51,063,000
• Market Cap: $1.74 billion
• Optionable: Optionable
• Beta: 0.71